Agios Pharmaceuticals Inc. buy melinda
Start price
24.03.19
/
50%
€56.06
Target price
04.11.21
€76.67
Performance (%)
-37.53%
End price
21.12.20
€35.02
Summary
This prediction ended on 21.12.20 with a price of €35.02. Massive losses of -37.53% were the result for the BUY prediction by melinda. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Agios Pharmaceuticals Inc. | 0.000% | 0.000% | 63.710% | 6.674% |
iShares Core DAX® | -2.385% | 3.986% | 16.836% | 16.377% |
iShares Nasdaq 100 | -4.527% | -0.258% | 18.824% | 29.987% |
iShares Nikkei 225® | -4.129% | 4.382% | 10.912% | -1.507% |
iShares S&P 500 | -2.885% | 1.387% | 20.391% | 35.258% |
According to melinda what are the pros and cons of Agios Pharmaceuticals Inc. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Agios Pharmaceuticals Inc. diskutieren
SecteurRecherche biotechnologique et médicale Agenda 29/03 Présentation
Agios Pharmaceuticals, Inc. est une société biopharmaceutique au stade clinique. Les domaines thérapeutiques de la Société sont le cancer et les maladies métaboliques génétiques rares, qui sont un groupe de plus de 600 maladies génétiques rares causées par des mutations, ou des défauts, de gènes métaboliques uniques. Les produits candidats de la Société pour le traitement du cancer sont l'énasidénib et l'ivosidénib (AG-120), qui ciblent respectivement l'isocitrate déshydrogénase 2 (IDH2) et l'isocitrate déshydrogénase 1 (IDH1) muté, et l'AG-881, qui cible tant l'IDH1 muté que l'IDH2 muté. Ces mutations se retrouvent dans une gamme de tumeurs hématologiques malignes et de tumeurs solides. Le produit candidat principal dans ses programmes AG-348, un trouble métabolique génétique rare, cible la pyruvate kinase-R pour le traitement de la carence en pyruvate kinase. La carence en pyruvate kinase est une maladie rare qui entraîne souvent une anémie hémolytique grave due à des mutations héréditaires de l'enzyme pyruvate kinase dans les globules rouges.
Nombre d'employés
: 382 personnes.
In the thread Trading Agios Pharmaceuticals Inc.
Buy beendet
Stopped prediction by melinda for Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€25.74
20.02.22
20.02.22
€30.00
20.03.22
20.03.22
2.76%
21.03.22
21.03.22
Could be worthwhile Investment >10% per year
Agios Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€35.02
21.12.20
21.12.20
€45.00
21.12.21
21.12.21
-13.14%
22.12.21
22.12.21
Could be worthwhile Investment >10% per year
Agios Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€72.13
30.08.18
30.08.18
€90.20
23.01.19
23.01.19
-36.26%
23.01.19
23.01.19
Could be worthwhile Investment >10% per year
Agios Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€59.21
14.09.17
14.09.17
€108.24
26.12.17
26.12.17
-11.80%
26.12.17
26.12.17
Could be worthwhile Investment >10% per year
Agios Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€65.65
14.09.17
14.09.17
€120.00
26.12.17
26.12.17
-11.80%
26.12.17
26.12.17
Could be worthwhile Investment >10% per year
Agios Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€52.41
29.08.17
29.08.17
€55.92
30.08.17
30.08.17
7.31%
30.08.17
30.08.17
Could be worthwhile Investment >10% per year
Agios Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€58.10
29.08.17
29.08.17
€62.00
30.08.17
30.08.17
7.31%
30.08.17
30.08.17
Could be worthwhile Investment >10% per year
Agios Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€43.49
30.05.17
30.05.17
€47.81
20.06.17
20.06.17
10.56%
20.06.17
20.06.17
Could be worthwhile Investment >10% per year
Agios Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€48.22
30.05.17
30.05.17
€53.00
20.06.17
20.06.17
10.56%
20.06.17
20.06.17
Could be worthwhile Investment >10% per year
Agios Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€44.13
25.04.17
25.04.17
€48.71
10.05.17
10.05.17
3.00%
10.05.17
10.05.17
Could be worthwhile Investment >10% per year
Agios Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€42.46
09.05.16
09.05.16
€48.71
31.05.16
31.05.16
16.74%
31.05.16
31.05.16
Could be worthwhile Investment >10% per year